Quantitative analysis of the expression of TGF-alpha and EGFR in papillary thyroid carcinoma: Clinicopathological relevance

Pathology

Volumn 43, Issue 1, 2011, Pages 40-47

  Lam, Alfred King Yin ^a   Lau, Kevin Kwok Pui ^b   Gopalan, Vinod ^a   Luk, John ^b   Lo, Chung Yau ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

EGFR; Papillary thyroid carcinoma; TGF

Indexed keywords

EID: 80052255082     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e328340bb46     Document Type: Article

References (36)

1. de Larco JE, Todaro GJ. Growth factors from murine sarcoma virustransformed cells. Proc Natl Acad Sci USA 1978; 75: 4001-5. (Pubitemid 8399860)
2. Massague J. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J Biol Chem 1983; 258: 13614-20. (Pubitemid 14211998)
3. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250-3. (Pubitemid 16066000)
4. Fan CY, Melhem MF, Hosal AS, et al. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127: 1075-9.
5. Daveau M, Scotte M, Francois A, et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 2003; 36: 130-41. (Pubitemid 36314790)
6. Konturek PC, Konturek SJ, Sulekova Z, et al. Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer. Aliment Pharmacol Ther 2001; 15: 989-99. (Pubitemid 32578971)
7. Pelletier S, Tanguay S, Lee S, et al. TGF-alpha as a candidate tumor antigen for renal cell carcinomas. Cancer Immunol Immunother 2009; 58: 1207-18.
8. Holting T, Siperstein AE, Clark OH, et al. Epidermal growth factor (EGF) and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 1995; 132: 229-35.
9. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43. (Pubitemid 29248872)
10. Fischer-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res 1997; 17: 613-9. (Pubitemid 27105536)
11. Klijn JG, Berns PM, Schmitz PI, et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 1992; 13: 3-17.
12. Lam AK, Lo CY, Lam KSL. Papillary carcinoma of thyroid: a 30-year clinicopathological review of the histological variants. Endocr Pathol 2005; 16: 323-30. (Pubitemid 43787108)
13. Lam KY, Lo CY, Leung PS. High prevalence of RET protooncogene activation (RET/PTC) in papillary thyroid carcinomas. Eur J Endocrinol 2002; 147: 741-5. (Pubitemid 36032962)
14. Croyle M, Akeno N, Knauf JA, et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res 2008; 68: 4183-91.
15. Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer 2006; 13: 1173-83. (Pubitemid 46212571)
16. Hall PA, Reis-Filho JS, Tomlinson IP, et al. An introduction to genes, genomes and disease. J Pathol 2010; 220: 109-13.
17. Sanford M, Scott LJ. Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer. Drugs 2009; 69: 2303-28.
18. Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 2006; 91: 3662-6. (Pubitemid 44402152)
19. Masago K, Asato R, Fujita S, et al. Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 2009; 124: 2744-9.
20. DeLellis RA, Williams ED. Tumours of the thyroid and parathyroid. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press, 2004; 49-56.
21. Lang BH, Lo CY, Chan WF, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 2007; 245: 366-78. (Pubitemid 46673133)
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8. (Pubitemid 34164012)
23. Aasland R, Akslen LA, Varhaug JE, et al. Co-expression of the genes encoding transforming growth factor-alpha and its receptor in papillary carcinomas of the thyroid. Int J Cancer 1990; 46: 382-7. (Pubitemid 20291089)
24. Haugen DR, Akslen LA, Varhaug JE, et al. Demonstration of a TGF-alpha- EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas. Int J Cancer 1993; 55: 37-43. (Pubitemid 23261703)
25. Akslen LA, Myking AO, Salvesen H, et al. Prognostic impact of EGFreceptor in papillary thyroid carcinoma. Br J Cancer 1993; 68: 808-12. (Pubitemid 23301291)
26. Ness GO, Haugen DR, Varhaug JE, et al. Cytoplasmic localization of EGF receptor in papillary thyroid carcinomas: association with the 150-kDa receptor form. Int J Cancer 1996; 65: 161-7. (Pubitemid 26051678)
27. Akslen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival. Cancer 1995; 76: 1643-54.
28. Gorgoulis V, Aninos D, Priftis C, et al. Expression of epidermal growth factor, transforming growth factor-alpha and epidermal growth factor receptor in thyroid tumors. In Vivo 1992; 6: 291-6.
29. van der Laan BF, Freeman JL, Asa SL. Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. Thyroid 1995; 5: 67-73.
30. Wiseman SM, Griffith OL, Melck A, et al. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. Am J Surg 2008; 195: 667-73. (Pubitemid 351540818)
31. Yu XM, Lo CY, Chan WF, et al. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res 2005; 11: 8063-9.
32. Pu YS, Huang CY, Kuo YZ, et al. Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma. J Biomed Sci 2009; 16: 82.
33. Piyathilake CJ, Frost AR, Manne U, et al. Differential expression of growth factors in squamous cell carcinoma and precancerous lesions of the lung. Clin Cancer Res 2002; 8: 734-44. (Pubitemid 34742102)
34. Salajegheh A, Petcu EB, Smith RA, et al. Follicular variant of papillary thyroid carcinoma: a diagnostic challenge for clinicians and pathologists. Postgrad Med J 2008; 84: 78-82. (Pubitemid 351427573)
35. Lam AK, Lo CY, Leung P, et al. Clinicopathological roles of alterations of tumor suppressor gene p16 in papillary thyroid carcinoma. Ann Surg Oncol 2007; 14: 1772-9. (Pubitemid 46790989)
36. Lo CY, Lam KY, Leung PP, et al. High prevalence of cyclooxygenase 2 expression in papillary thyroid carcinoma. Eur J Endocrinol 2005; 152: 545-50. (Pubitemid 40575799)